Dementia in Neuroscience: Departement of Neurology Christian University of Indonesia Medical Faculty
Dementia in Neuroscience: Departement of Neurology Christian University of Indonesia Medical Faculty
Dementia in Neuroscience: Departement of Neurology Christian University of Indonesia Medical Faculty
NEUROSCIENCE
DEPARTEMENT OF NEUROLOGY
CHRISTIAN UNIVERSITY OF INDONESIA
MEDICAL FACULTY
DEFINITION OF
DEMENTIA
DEMENTIA- the disease with acquired
deterioration in cognitive/ intellectual
abilities without impairment of
consciousness
Cognitive deficit represent a decline
from previous level of functioning
DSM IV DIAGNOSTIC
CRITERIA
1. Memory impairment
2. At least one of the following:
Aphasia
Apraxia
Agnosia
Disturbance in executive functioning
6.
skills
2.
3.
4.
5.
7.
Misplacing things
8.
Changes in mood or
behavior
9.
Changes in personality
EPIDEMIOLOGY
Vascular dementia 5 20
%
~ 5 to 8 % at age 65 to 70
~ 15 to 20 % at age 75 to 80
up to 40 to 50 % over age 85
ETIOLOGY
NEURODEGENERATIVE
VASCULAR
NEUROLOGICAL
ENDOCRINE
Hypothyroidism
NUTRITIONAL
INFECTIOUS
METABOLIC
TRAUMATIC
TOXIC AGENTS
Subcortical
MIXED
Both cortical and sub-cortical area
involved.
Example: vascular dementia, Dementia
with Lewy bodies, Corticobasal
degeneration, Neurosyphilis
Reversible DEMENTIA
D=
E=
M=
E=
N=
T=
I=
A=
Delirium
Emotions (depression)& Endocrine Disease
Metabolic Disturbances
Eye & Ear Impairments
Nutritional Disorders
Tumors, Toxicity, Trauma to Head
Infectious Disorders
Alcohol, Arteriosclerosis
Irreversible DEMENTIA
Alzheimers
Lewy Body Dementia
Picks Disease (Frontotemperal Dementia)
Parkinsons
Vascular
Huntingtons Disease
Jacob-Cruzefeldt Disease
How to diagnose
dementia in neurology
Clinical history
Symptoms analysis
Focussed physical examination
Cognitive and neuropsychiatric examination
Laboratory evaluation
CLINICAL SYMPTOMS
FOCUSED HISTORY
Chronology of the problem
- mode of onset abrupt vs gradual
- progression - stepwise vs continous decline
- duration of symptoms
Medical history
Family history
Socio-economic history
Evaluation for toxic agent exposure
PHYSICAL
EXAMINATION
Neurological examination-mobility and balance
assessment
Focal neurological deficits
Extra-pyramidal signs
Vision & hearing screening
Cardiac and pulmonary evaluation
COGNITIVE &
NEUROPSYCHIATRIC
EXAMINATION
MMSE
SCORE RANGE
24-30
18-23
10-17
< 10
Normal
Mild
Moderate
Severe
INVESTIGATIONS
ASSESSMENTS
RATIONALE
Neurological examination
Correlate imaging
findings with clinical
examination
Neuropsychological testing
Mini-Mental State
Examination: Screening
test of cognitive
function
DIFFERENTIAL
DIAGNOSIS
DIAGNOSTIC APPROACH
COGNITIVE IMPAIRMENT ?
YES
DETERIORATION FROM A
PREVIOUSLY HIGHER LEVEL ?
NO
MENTAL
RETARDATION
YES
DELIRIUM
NO
APHASIA
AMNESTIC D/O, etc
YES
CONSCIOUSNESS ALTERED?
NO
MULTIPLE COGNITIVE FUNCTIONS
INVOLVED ?
YES
DEMENTIA
Alzheimers disease
Vascular dementia
(dementia
due to
strokes).
disease
Barry Reisberg, MD and colleagues
New York University Medical Center's Aging and Dementia Research Center
Functional Assessment Staging (FAST) scaleallows professionals and caregivers to chart the decline of people with
Alzheimer's disease.
CLINICAL
MANIFESTATION
Begin with memory impairment
language
visuospatial skills
Anosognosia- unaware of difficulties
Cognitive decline-driving,shopping,house-keeping
Language impaired - naming, comprehension then
- fluency
Apraxia - sequence motor task cant perform
Visuospatial deficits
Delusions ,capgras syndrome late stages
End stage-rigid,mute , incontinent & bed-ridden
AD DIAGNOSIS
Neurological exam & neuropsychological testing
Brain imaging: brain atrophy due to extensive
neuronal loss and hippocampal atrophy
Diagnosis confirmed by histology of post-mortem
brain
Plaques & tangles in hippocampus & cerebral
cortex.
Neuritic plaques
Neurofibrilarry tangles
VASCULAR DEMENTIA
Refers to cognitive decline caused by ischemic, hemorrhagic, or
oligemic injury to the brain as a consequence of cerebrovascular
or cardiovascular disease.
Part of a spectrum of vascular disease causing cognitive
impairment, which also includes mild cognitive impairment of
vascular origin & mixed Alzheimer's disease plus cerebrovascular
disease.
Kraepelin first described arteriosclerotic dementia in 1896
DIAGNOSIS
&
CLINICAL
FEATURES
(NINDSAIREN)
OTHER TYPES OF
DEMENTIA
Vascular dementia
Frontotemporal dementia
Lewy Body dementia
VASCULAR DEMENTIA
Frontotemporal Dementias
Often begins with marked behavioral disturbances, unlike AD
Classic form Picks disease
Patients frequently hot-tempered and socially disinhibited
memory & visuo spatial skills spared
Impaired planning,judgement and language
Echolalia +
Overlap with PSP,CBD, motor neuron disease
Illness progresses for years, like AD
Inevitable decline
MRI- lobar atrophy of frontal and/or temporal
About 50% of patients have family history
TREATMENT FOR
DEMENTIA
Cholinesterasi Inhibitor
Donepezil (Aricept)
Rivastigmine (Exelon)
Galantamine (Reminyl)
Memantine
Ebixa
Axura
MEDICATION TO AVOID
IN ALL PATIENTS WITH
DEMENTIA
(Dementia and Cognitive Impairment Diagnosis and Treatment
Guideline.
Available
at
https://www.ghc.org/allsites/guidelines/dementia.pdf)
MEDICATION
RATIONALE
Antispasmodics
Atropine, belladonna alkaloids, dicyclomine, hyosciscyamine,
scopolamine, propantheline
Antimuscarinics
Darifenacin, fesoterodine, flavoxate, oxybutynin, solifenacin,
tolterodine, trospium
Antihistamines
Brompheniramine, chlorpheniramine, clemastine, cyproheptadine,
diphenhydramine, hydroxyzine, loratadine
Antiemetics
Dimenhydrinate, meclizine, promethazine
H2-receptor antagonists
Ranitidine, cimetidine, famotidine
Antiparkinsonian anticholinergics
Benztropine, trihexyphenidyl
Antiarrhythmics
Disopyramide
Potent negative inotrope; may induce heart failure in older adults. Strong
anticholinergic effects
Narcotic analgesics
Meperidine, pentazocine
Increased CNS effects leading to increased confusion and toxicity risk. Safer
alternatives available
Anxiolytics
All benzodiazepines
Sleep agents
Zolpidem